- Home
- HCIC vs CCCC Comparison
HCIC vs CCCC Comparison
Compare HCIC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCIC | CCCC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.6M | 404.7M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HCIC | CCCC |
|---|---|---|
| Price | $9.97 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 16.9K | ★ 4.1M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $9.93 | $1.69 |
| 52 Week High | $10.01 | $5.17 |
Technical Indicators
Market Signals| Indicator | HCIC | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 37.86 |
| Support Level | N/A | $2.34 |
| Resistance Level | $9.99 | $3.89 |
| Average True Range (ATR) | 0.02 | 0.30 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 53.33 | 1.94 |
Price Performance
Historical ComparisonAbout HCIC Hennessy Capital Investment Corp. VIII Class A Ordinary Shares
Hennessy Capital Investment Corp VIII is a blank check company.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.